Comparative Pharmacology
Head-to-head clinical analysis: JYLAMVO versus TIBSOVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JYLAMVO versus TIBSOVO.
JYLAMVO vs TIBSOVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
500 mg orally once daily taken with or without food.
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent